Mutual Advisors LLC Has $262,000 Stake in Edwards Lifesciences Corporation $EW

Mutual Advisors LLC decreased its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 6.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,281 shares of the medical research company’s stock after selling 217 shares during the period. Mutual Advisors LLC’s holdings in Edwards Lifesciences were worth $262,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of EW. Quantbot Technologies LP bought a new position in shares of Edwards Lifesciences during the 1st quarter worth about $26,000. SouthState Corp bought a new position in shares of Edwards Lifesciences during the 1st quarter worth about $27,000. Tradewinds Capital Management LLC increased its holdings in shares of Edwards Lifesciences by 102.5% during the 1st quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company’s stock worth $29,000 after purchasing an additional 205 shares during the period. Rossby Financial LCC bought a new position in shares of Edwards Lifesciences during the 1st quarter worth about $29,000. Finally, Costello Asset Management INC bought a new position in shares of Edwards Lifesciences during the 1st quarter worth about $29,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Activity

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of the company’s stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at approximately $1,748,278.92. This represents a 15.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Larry L. Wood sold 8,950 shares of the company’s stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the transaction, the insider owned 206,900 shares in the company, valued at $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.34% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have recently issued reports on EW. Evercore ISI set a $88.00 price objective on shares of Edwards Lifesciences and gave the stock an “outperform” rating in a report on Tuesday, October 7th. JPMorgan Chase & Co. boosted their price objective on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the stock a “neutral” rating in a report on Friday, July 25th. Mizuho boosted their price objective on shares of Edwards Lifesciences from $87.00 to $95.00 and gave the stock an “outperform” rating in a report on Friday, July 25th. Piper Sandler upped their target price on shares of Edwards Lifesciences from $83.00 to $90.00 and gave the company an “overweight” rating in a research note on Friday, July 25th. Finally, Stifel Nicolaus set a $85.00 target price on shares of Edwards Lifesciences and gave the company a “buy” rating in a research note on Monday, September 22nd. Three analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $87.06.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock opened at $76.03 on Wednesday. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $44.64 billion, a price-to-earnings ratio of 10.94, a P/E/G ratio of 3.61 and a beta of 1.05. Edwards Lifesciences Corporation has a 1-year low of $64.89 and a 1-year high of $83.00. The firm’s 50-day moving average price is $77.46 and its two-hundred day moving average price is $76.25.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.05. The firm had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, equities analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.